Brian E. Zimmerman

Brian E. Zimmerman

Auto-generated profile, based on publicly available information

Brian E. Zimmerman

Physical Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899-8462, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2010 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
BZBrian E. Zimmerman
Brian E. Zimmerman
JCJeffrey T. Cessna
Jeffrey T. Cessna
We have developed a methodology for calibrating 68Ge radioactivity content in a commercially available calibration source for activity calibrators in a way that is traceable to the national standard. Additionally, the source was cross-calibrated for equivalent 18F content by direct comparison with the national standard for 18F in the same geometry. Methods: Sources containing standardized 68GeCl4 or 18F-FDG solutions were prepared at the National Institute of Standards and Technology (NIST) with mock syringe blanks used in the construction of a commercially available epoxy-based 68Ge calibration source. These sources and several NIST-constructed epoxy-based 68Ge mock syringes were then used as artifact standards to determine calibration factors for NIST-maintained activity calibrators and secondary standard ionization chambers to enable calibration of the actual commercial sources. A direct comparison between the solution-based 68Ge sources and the 18F-FDG sources allowed for an empiric determination of the relative response for these radionuclides in several commercial activity calibrators. Potential measurement effects due to differences between the solution composition and the epoxy and theoretic 68Ge-to-18F response ratios were studied by Monte Carlo simulation. Results: The calibration factors developed in this study enabled NIST to calibrate epoxy-based mock syringe sources with a relative combined standard uncertainty of 0.52%. The direct comparisons of the 68Ge and 18F standards in the various ionization chambers allowed the activity to be expressed in terms of equivalent 18F activity with a relative combined standard uncertainty of about 0.9%. Conclusion: The ability for NIST to calibrate these epoxy-based mock syringes enabled, for the first time to our knowledge, the direct traceability to the national 68Ge standard to be established for this type of source. Through a direct comparison with the NIST 18F standard, the determination of the relative response ratios in activity calibrators enabled the equivalent 18F activity to be determined in a way that was also traceable to the national 18F activity standard.

8 December 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MLMengshi Li
Mengshi Li
ESEdwin A. Sagastume
Edwin A. Sagastume
DLDongyoul Lee
Dongyoul Lee
DMDaniel McAlister
Daniel McAlister
ADAnthony J. DeGraffenreid
Anthony J. DeGraffenreid
MSMichael Schultz
Michael Schultz
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage. Recent clinical studies provide compelling evidence that alpha-TRT has the potential to deliver a significantly more potent anti-cancer effect compared with beta-TRT. Generator-produced 212Pb (which decays to alpha emitters 212Bi and 212Po) is a particularly promising radionuclide for receptor-targeted alpha-particle therapy. A second attractive feature that distinguishes 212Pb alpha-TRT from other available radionuclides is the possibility to employ elementallymatched isotope 203Pb as an imaging surrogate in place of the therapeutic radionuclide. As direct non-invasive measurement of alpha-particle emissions cannot be conducted using current medical scanner technology, the imaging surrogate allows for a pharmacologically-inactive determination of the pharmacokinetics and biodistribution of TRT candidate ligands in advance of treatment. Thus, elementally-matched 203Pb labeled radiopharmaceuticals can be used to identify patients who may benefit from 212Pb alpha-TRT and apply appropriate dosimetry and treatment planning in advance of the therapy. In this review, we provide a brief history on the use of these isotopes for cancer therapy; describe the decay and chemical characteristics of 203/212Pb for their use in cancer theranostics and methodologies applied for production and purification of these isotopes for radiopharmaceutical production. In addition, a medical physics and dosimetry perspective is provided that highlights the potential of 212Pb for alpha-TRT and the expected safety for 203Pb surrogate imaging. Recent and current preclinical and clinical studies are presented. The sum of the findings herein and observations presented provide evidence that the 203Pb/212Pb theranostic pair has a promising future for use in radiopharmaceutical theranostic therapies for cancer.

1 June 2017 in Zeitschrift für Medizinische Physik
Verified
Journal Article
Open access
BZBrian E. Zimmerman
Brian E. Zimmerman
DGDarko Grošev
Darko Grošev
IBIrene Buvat
Irene Buvat
MPMarco A. Coca Pérez
Marco A. Coca Pérez
EFEric C. Frey
Eric C. Frey
GPGian Luca Gian Poli
Gian Luca Gian Poli
Accurate quantitation of activity provides the basis for internal dosimetry of targeted radionuclide therapies. This study investigated quantitative imaging capabilities at sites with a variety of experience and equipment and assessed levels of errors in activity quantitation in Single-Photon Emission Computed Tomography (SPECT) and planar imaging. Participants from 9 countries took part in a comparison in which planar, SPECT and SPECT with X ray computed tomography (SPECT-CT) imaging were used to quantify activities of four epoxy-filled cylinders containing 133Ba, which was chosen as a surrogate for 131I. The sources, with nominal volumes of 2, 4, 6 and 23mL, were calibrated for 133Ba activity by the National Institute of Standards and Technology, but the activity was initially unknown to the participants. Imaging was performed in a cylindrical phantom filled with water. Two trials were carried out in which the participants first estimated the activities using their local standard protocols, and then repeated the measurements using a standardized acquisition and analysis protocol. Finally, processing of the imaging data from the second trial was repeated by a single centre using a fixed protocol. In the first trial, the activities were underestimated by about 15% with planar imaging. SPECT with Chang's first order attenuation correction (Chang-AC) and SPECT-CT overestimated the activity by about 10%. The second trial showed moderate improvements in accuracy and variability. Planar imaging was subject to methodological errors, e.g., in the use of a transmission scan for attenuation correction. The use of Chang-AC was subject to variability from the definition of phantom contours. The project demonstrated the need for training and standardized protocols to achieve good levels of quantitative accuracy and precision in a multicentre setting. Absolute quantification of simple objects with no background was possible with the strictest protocol to about 6% with planar imaging and SPECT (with Chang-AC) and within 2% for SPECT-CT.

1 February 2004 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
BZB.E. Zimmerman
B.E. Zimmerman
JCJ.T. Cessna
J.T. Cessna
MMM.A. Millican
M.A. Millican

1 September 2008 in Journal of Research of the National Institute of Standards and Technology
Verified
Journal Article
Closed access
BZB. E. Zimmerman
B. E. Zimmerman
JCJ. T. Cessna
J. T. Cessna
RFR. Fitzgerald
R. Fitzgerald
A solution containing (68)Ge in equilibrium with its daughter, (68)Ga, has been standardized for the first time at the National Institute of Standards and Technology (NIST) using 3 liquid scintillation-based techniques: live-timed 4πβ -γ anticoincidence (LTAC) counting, the Triple-to-Double Coincidence Ratio (TDCR) method, and (3)H-standard efficiency tracing with the CIEMAT(1)/NIST (CNET) method. The LTAC technique is much less dependent on level scheme data and model-dependent parameters and was thus able to provide a reference activity concentration value for the master solution with a combined standard uncertainty of about 0.3 %. The other two methods gave activity concentration values with respective differences from the reference value of +1.2 % and -1.5 %, which were still within the experimental uncertainties. Measurements made on the NIST "4π"γ secondary standard ionization chamber allowed for the determination of calibration factors for that instrument, allowing future calibrations to be made for (68)Ge/(68)Ga without the need for a primary measurement. The ability to produce standardized solutions of (68)Ge presents opportunities for the development of a number of NIST-traceable calibration sources with very low (<1 %) relative standard uncertainties that can be used in diagnostic medical imaging.

1 January 1995 in Physica Scripta
Verified
Journal Article
Closed access
WRW Reviol
W Reviol
LRL L Riedinger
L L Riedinger
JLJ M Lewis
J M Lewis
WMW F Mueller
W F Mueller
CBC R Bingham
C R Bingham
BZB E Zimmerman
B E Zimmerman